ATE531371T1 - Kombinationen von therapeutischen wirkstoffen zur krebsbehandlung - Google Patents
Kombinationen von therapeutischen wirkstoffen zur krebsbehandlungInfo
- Publication number
- ATE531371T1 ATE531371T1 AT05853820T AT05853820T ATE531371T1 AT E531371 T1 ATE531371 T1 AT E531371T1 AT 05853820 T AT05853820 T AT 05853820T AT 05853820 T AT05853820 T AT 05853820T AT E531371 T1 ATE531371 T1 AT E531371T1
- Authority
- AT
- Austria
- Prior art keywords
- inhibitor
- kinase inhibitor
- combinations
- active ingredients
- cancer treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000004480 active ingredient Substances 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 abstract 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 1
- 102000029749 Microtubule Human genes 0.000 abstract 1
- 108091022875 Microtubule Proteins 0.000 abstract 1
- 229940079156 Proteasome inhibitor Drugs 0.000 abstract 1
- 229940123690 Raf kinase inhibitor Drugs 0.000 abstract 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 229940100198 alkylating agent Drugs 0.000 abstract 1
- 239000002168 alkylating agent Substances 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000002814 antineoplastic antimetabolite Substances 0.000 abstract 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 229940121647 egfr inhibitor Drugs 0.000 abstract 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 abstract 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005865 ionizing radiation Effects 0.000 abstract 1
- 229940123729 mTOR kinase inhibitor Drugs 0.000 abstract 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 abstract 1
- 210000004688 microtubule Anatomy 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- 102000051624 phosphatidylethanolamine binding protein Human genes 0.000 abstract 1
- 108700021017 phosphatidylethanolamine binding protein Proteins 0.000 abstract 1
- -1 platin compound Chemical class 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 239000003207 proteasome inhibitor Substances 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 abstract 1
- 239000002525 vasculotropin inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63643904P | 2004-12-15 | 2004-12-15 | |
| PCT/US2005/044993 WO2006065780A2 (en) | 2004-12-15 | 2005-12-13 | Combinations of therapeutic agents for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE531371T1 true ATE531371T1 (de) | 2011-11-15 |
Family
ID=36463409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05853820T ATE531371T1 (de) | 2004-12-15 | 2005-12-13 | Kombinationen von therapeutischen wirkstoffen zur krebsbehandlung |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8975248B2 (enExample) |
| EP (1) | EP1827437B1 (enExample) |
| JP (1) | JP5345323B2 (enExample) |
| KR (1) | KR101367516B1 (enExample) |
| CN (1) | CN101080227B (enExample) |
| AT (1) | ATE531371T1 (enExample) |
| AU (1) | AU2005316652B2 (enExample) |
| BR (1) | BRPI0515774A (enExample) |
| CA (1) | CA2589521C (enExample) |
| CY (1) | CY1112368T1 (enExample) |
| DK (1) | DK1827437T3 (enExample) |
| ES (1) | ES2374828T3 (enExample) |
| HR (1) | HRP20110960T1 (enExample) |
| IL (1) | IL183595A0 (enExample) |
| MA (1) | MA29096B1 (enExample) |
| MX (1) | MX2007007212A (enExample) |
| NO (1) | NO20073552L (enExample) |
| NZ (1) | NZ555370A (enExample) |
| PL (1) | PL1827437T3 (enExample) |
| PT (1) | PT1827437E (enExample) |
| RU (1) | RU2400232C2 (enExample) |
| SI (1) | SI1827437T1 (enExample) |
| TN (1) | TNSN07224A1 (enExample) |
| TW (1) | TW200628151A (enExample) |
| WO (1) | WO2006065780A2 (enExample) |
| ZA (1) | ZA200704701B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120104412A (ko) | 2002-09-06 | 2012-09-20 | 인설트 테라페틱스, 인코퍼레이티드 | 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체 |
| DK1827437T3 (da) | 2004-12-15 | 2012-02-13 | Sigma Tau Ind Farmaceuti | Kombinationer af terapeutiske midler til cancerbehandling |
| US20080219977A1 (en) * | 2005-07-27 | 2008-09-11 | Isaiah Josh Fidler | Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer |
| EP2275103B1 (en) | 2005-11-21 | 2014-04-23 | Novartis AG | mTOR inhibitors in the treatment of endocrine tumors |
| WO2007094026A1 (en) * | 2006-02-17 | 2007-08-23 | Paolo La Colla | Prophylactic and/or therapeutic treatment of proliferative and conformational diseases |
| AU2007234382B2 (en) * | 2006-04-05 | 2011-06-09 | Novartis Ag | Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer |
| AU2007234379A1 (en) * | 2006-04-05 | 2007-10-11 | Novartis Ag. | Combinations of therapeutic agents for treating cancer |
| CN102671196B (zh) | 2006-04-05 | 2014-12-03 | 诺华股份有限公司 | 用于治疗癌症的治疗剂的组合 |
| JP2010516625A (ja) | 2007-01-24 | 2010-05-20 | インサート セラピューティクス， インコーポレイテッド | 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート |
| EP2060565A1 (en) * | 2007-11-16 | 2009-05-20 | 4Sc Ag | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
| AU2009225434B2 (en) | 2008-03-21 | 2014-05-22 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
| CN101837129B (zh) * | 2009-03-19 | 2012-12-12 | 鼎泓国际投资（香港）有限公司 | 含cMet抑制剂、HDAC抑制剂与EGFR酪氨酸激酶抑制剂的药物组合物及其应用 |
| US20120114658A1 (en) * | 2009-09-15 | 2012-05-10 | John Ryan | Treatment of cancer |
| JP5801378B2 (ja) * | 2010-04-19 | 2015-10-28 | ニーキ ファーマ インコーポレイテッド | プロテアソーム阻害剤およびガリウム錯体を用いた併用療法 |
| BR122017028566B1 (pt) * | 2010-11-12 | 2022-03-03 | Pharma Mar, S.A. | Uso de pm01183, ou um sal farmaceuticamente aceitável do mesmo, em combinação sinérgica com um antibiótico anticâncer e kit |
| CN102731516B (zh) * | 2011-04-07 | 2014-07-02 | 宁波天衡药业股份有限公司 | 一类具有抗肿瘤活性的喜树碱衍生物 |
| WO2014055493A1 (en) | 2012-10-02 | 2014-04-10 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
| WO2015152409A1 (ja) * | 2014-04-04 | 2015-10-08 | 大鵬薬品工業株式会社 | タキサン系化合物を含有する抗腫瘍剤及び抗腫瘍効果増強剤 |
| SG11201608303QA (en) | 2014-04-04 | 2016-11-29 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| US20180140620A1 (en) | 2015-06-15 | 2018-05-24 | Newsouth Innovations Pty Limited | Pharmaceutical Combinations of Organo-Arsenoxide Compounds and mTOR Inhibitors |
| CN107951888A (zh) * | 2017-12-19 | 2018-04-24 | 天津科技大学 | 阿法替尼与10-羟基喜树碱的药物组合及其应用 |
| CN109091480A (zh) * | 2018-09-19 | 2018-12-28 | 天津科技大学 | 癌组合物10-羟基喜树碱和克唑替尼治疗肺癌及用途 |
| KR20210107069A (ko) * | 2018-12-21 | 2021-08-31 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 컨쥬게이트와 키나아제 저해제의 조합 |
| CN111789903A (zh) * | 2019-04-08 | 2020-10-20 | 石小和 | 治疗尿道癌的药物组合物及其制备方法 |
| EP4061372A1 (en) | 2019-11-21 | 2022-09-28 | Pharma Mar, S.A. | Methods of treating small cell lung cancer with lurbinectedin formulations |
| CN120695174A (zh) * | 2021-07-01 | 2025-09-26 | 江苏先声生物制药有限公司 | 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用 |
| WO2023165603A1 (en) * | 2022-03-03 | 2023-09-07 | Zai Lab (Shanghai) Co., Ltd. | Dna-pk inhibitor and combination use thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69531722T2 (de) | 1994-11-11 | 2004-07-01 | Debiopharm S.A. | Karzinostatische Zusammensetzungen, welche Cis-Oxaliplatin und eine oder mehrere andere verträgliche Karzinostatika enthalten |
| JPH08169825A (ja) * | 1994-12-15 | 1996-07-02 | Tanaka Kikinzoku Kogyo Kk | 抗癌剤の併用投与方法及び併用可能な抗癌剤 |
| SE9704545D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| US20020103141A1 (en) | 1998-12-23 | 2002-08-01 | Mckearn John P. | Antiangiogenic combination therapy for the treatment of cancer |
| US7105492B2 (en) * | 1999-03-09 | 2006-09-12 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Camptothecin derivatives having antitumor activity |
| PT1044977E (pt) * | 1999-03-09 | 2002-09-30 | Sigma Tau Ind Farmaceuti | Derivados de camptotecina com actividade antitumoral |
| GB0119249D0 (en) * | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
| WO2003037897A2 (en) | 2001-10-29 | 2003-05-08 | Novartis Ag | Use of 7h-pyrrolo[2,3-d]pyrimidine derivatives in the treatment of solid tumor diseases |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| HRP20050115A2 (en) * | 2002-07-11 | 2005-10-31 | Combinatorx | Combinations of drugs for the treatment of neoplasms |
| MXPA05012464A (es) * | 2003-05-21 | 2006-01-30 | Novartis Ag | Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos. |
| WO2005117980A1 (en) * | 2004-06-04 | 2005-12-15 | Pfizer Products Inc. | Method for treating abnormal cell growth |
| DK1827437T3 (da) | 2004-12-15 | 2012-02-13 | Sigma Tau Ind Farmaceuti | Kombinationer af terapeutiske midler til cancerbehandling |
| JP4702322B2 (ja) | 2006-12-14 | 2011-06-15 | トヨタ自動車株式会社 | 内燃機関の制御装置 |
-
2005
- 2005-12-13 DK DK05853820.8T patent/DK1827437T3/da active
- 2005-12-13 BR BRPI0515774-9A patent/BRPI0515774A/pt active Search and Examination
- 2005-12-13 CA CA2589521A patent/CA2589521C/en not_active Expired - Fee Related
- 2005-12-13 NZ NZ555370A patent/NZ555370A/en not_active IP Right Cessation
- 2005-12-13 ES ES05853820T patent/ES2374828T3/es not_active Expired - Lifetime
- 2005-12-13 MX MX2007007212A patent/MX2007007212A/es active IP Right Grant
- 2005-12-13 JP JP2007546818A patent/JP5345323B2/ja not_active Expired - Fee Related
- 2005-12-13 PT PT05853820T patent/PT1827437E/pt unknown
- 2005-12-13 KR KR1020077013401A patent/KR101367516B1/ko not_active Expired - Fee Related
- 2005-12-13 AT AT05853820T patent/ATE531371T1/de active
- 2005-12-13 HR HR20110960T patent/HRP20110960T1/hr unknown
- 2005-12-13 AU AU2005316652A patent/AU2005316652B2/en not_active Ceased
- 2005-12-13 US US11/720,776 patent/US8975248B2/en not_active Expired - Fee Related
- 2005-12-13 CN CN2005800429798A patent/CN101080227B/zh not_active Expired - Lifetime
- 2005-12-13 SI SI200531442T patent/SI1827437T1/sl unknown
- 2005-12-13 PL PL05853820T patent/PL1827437T3/pl unknown
- 2005-12-13 RU RU2007126978/14A patent/RU2400232C2/ru not_active IP Right Cessation
- 2005-12-13 EP EP05853820A patent/EP1827437B1/en not_active Expired - Lifetime
- 2005-12-13 WO PCT/US2005/044993 patent/WO2006065780A2/en not_active Ceased
- 2005-12-14 TW TW094144288A patent/TW200628151A/zh unknown
-
2007
- 2007-05-31 IL IL183595A patent/IL183595A0/en unknown
- 2007-06-07 ZA ZA200704701A patent/ZA200704701B/xx unknown
- 2007-06-14 TN TNP2007000224A patent/TNSN07224A1/fr unknown
- 2007-06-18 MA MA29998A patent/MA29096B1/fr unknown
- 2007-07-09 NO NO20073552A patent/NO20073552L/no not_active Application Discontinuation
-
2012
- 2012-01-20 CY CY20121100074T patent/CY1112368T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20073552L (no) | Kombinasjoner av terapeutiske midler for behandling av kreft | |
| NO20061777L (no) | Kombinasjon av en VEGF-resptorinhibitor og er kjemopteraputisk middel | |
| Ferrario et al. | Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model | |
| RU2008152435A (ru) | Композиции и способы регулирования развития сосудов | |
| MXPA05013642A (es) | Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer. | |
| BRPI0418745A (pt) | anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente | |
| CY1112907T1 (el) | Συνδυασμοι και τροποι χορηγησης θεραπευτικων παραγοντων και θεραπεια συνδυασμου | |
| EA200600921A1 (ru) | Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний | |
| EA200801309A1 (ru) | ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ | |
| Wei et al. | Effect of captopril on radiation-induced TGF-β1 secretion in EA. Hy926 human umbilical vein endothelial cells | |
| DE60324431D1 (de) | Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata- oder gebahrmutterkrebs | |
| DE60320398D1 (de) | Methoden und medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs | |
| ATE381930T1 (de) | Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor | |
| Agrawal et al. | Brucine, a plant derived alkaloid inhibits inflammatory angiogenesis in a murine sponge model | |
| RU99126204A (ru) | Способ лечения рака легкого | |
| ATE484280T1 (de) | Verwendung der kombination aus temozolomid und tnf-alpha zur behandlung von glioblastoma | |
| AR063459A1 (es) | Metodo para administrar un inhibidor de aurora en el tratamiento del cancer | |
| DE60334289D1 (de) | Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen | |
| RU2005110536A (ru) | Способ лечения рака | |
| Osiecka et al. | Determination of basic fibroblast growth factor levels in serum of tumor-bearing BALB/c mice treated with photodynamic therapy | |
| Malik et al. | CPQ Medicine (2018) 2: 2 Research Article | |
| DK1687642T3 (da) | Screeningsfremgangsmåder til kombinationer af biologiske forbindelser | |
| ATE338560T1 (de) | Pharmazeutische zusammentsetzung zur medizinischen behandlung von gutartiger prostathyperplasie, dessen vorbereitungsmethode und dessen therapeutische verwendung | |
| EA202092513A1 (ru) | Комбинированная терапия | |
| TW200503798A (en) | Arsenic-containing pharmaceutical composition for treatment of tumor/cancer in conjunction with radiation therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1827437 Country of ref document: EP |